TITLE:

Prevalence of plasmid-mediated AmpC β -lactamase-producing *Escherichia coli* and spread of the ST131 clone among extended-spectrum β -lactamase-producing *E. coli* in Japan.

AUTHOR(S):

Matsumura, Yasufumi; Yamamoto, Masaki; Higuchi, Takeshi; Komori, Toshiaki; Tsuboi, Fusayuki; Hayashi, Akihiko; Sugimoto, Yoshihisa; ... Nagao, Miki; Takakura, Shunji; Ichiyama, Satoshi

CITATION:

Matsumura, Yasufumi ...[et al]. Prevalence of plasmid-mediated AmpC β -lactamase-producing *Escherichia coli* and spread of the ST131 clone among extended-spectrum β -lactamase-producing *E. coli* in Japan.. International journal of antimicrobial agen ...

ISSUE DATE:

2012-08

URL:

<http://hdl.handle.net/2433/178036>

RIGHT:

© 2012 Elsevier B.V.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

Short communication

Title: Prevalence of plasmid-mediated AmpC β -lactamase-producing *Escherichia coli* and spread of the ST131 clone among extended-spectrum β -lactamase-producing *E. coli* in Japan

Authors: Yasufumi Matsumura^a, Masaki Yamamoto^a, Takeshi Higuchi^a, Toshiaki Komori^b, Fusayuki Tsuboi^c, Akihiko Hayashi^d, Yoshihisa Sugimoto^e, Goh Hotta^a, Aki Matsushima^a, Miki Nagao^a, Shunji Takakura^a, and Satoshi Ichiyama^a

Affiliation: ^aDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan

^bDepartment of Infection Control and Clinical Laboratory, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, Japan

^cDepartment of Clinical Laboratory, Nagahama City Hospital, 313 Ooinui-cho, Nagahama-shi, Shiga, Japan

^dDepartment of Clinical Laboratory, Kyoto City Hospital, 1-2 Mibuhigashi-Takadacho, Nakagyo-ku, Kyoto, Japan

^eDepartment of Clinical Laboratory, Kohka Public Hospital, 3-39 Rokushin, Minakuchi-cho, Kohka, Shiga, Japan

Corresponding Author: Yasufumi Matsumura

Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine
54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

TEL: +81-75-751-4914; FAX: +81-75-751-3233

E-mail: yazblood@kuhp.kyoto-u.ac.jp

Abstract

In 2010, a total of 1327 clinical *Escherichia coli* isolates were analysed by PCR in 5 hospitals in the Kyoto and Shiga regions of Japan. The prevalence of plasmid-mediated AmpC β -lactamase (pAmpC) producers, extended-spectrum β -lactamase (ESBL) producers, and co-producers of pAmpC and ESBL were 1.7%, 9.7%, and 0.3%, respectively. Less than half of the pAmpC producers were reported to be resistant to third-generation cephalosporins, cephamycins, and β -lactam/ β -lactam inhibitors with the old CLSI breakpoints in 2009. CMY-2 was the most prevalent pAmpC type (95%), and CTX-M-14 (38%), CTX-M-15 (26%), and CTX-M-27 (19%) were the most prevalent ESBL types. The worldwide O25b-ST131-B2 clone accounted for 11% of pAmpC producers and 41% of ESBL producers. The O25b-ST131-B2 clone was characterised by a CTX-M-27 or CTX-M-15 type ESBL and ciprofloxacin non-susceptibility with quadruple mutations in quinolone resistance-determining regions (S83L and D87N in GyrA and S80I and E84V in ParC). A significant proportion of pAmpC producers and the O25b-ST131-B2 clone were found in Japan by a recent regional surveillance program.

Keywords: ESBL, AmpC, ST131, CTX-M-27, prevalence

1. Introduction

In recent years, the prevalence of extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* has increased dramatically worldwide [1]. A CTX-M-15 ESBL-producing *E. coli* with sequence type 131 (ST131) belonging to the O25b serogroup and the B2 phylogenetic group has emerged as an international pandemic clone[2]. The prevalence of plasmid-mediated AmpC β -lactamase (pAmpC)-producing *E. coli* has likewise been increasing [3]. As standard guidelines for detecting pAmpC remain unavailable, pAmpC producers are rarely identified in routine laboratory practices. However, the current data for the ST131 clone and pAmpC-producing *E. coli* in Japan are poor. In this study, we investigated the prevalence and characteristics of the ST131 clone and pAmpC-producing *E. coli* in the Kyoto and Shiga regions of Japan.

2. Materials and methods

2.1. Bacterial isolates

This study was conducted at 5 acute care hospitals in Japan: 3 municipal hospitals and 2 university hospitals in the Kyoto and Shiga regions of Japan. All of the *E. coli* isolates collected from both in-patients and out-patients between June 2010 and December 2010 were eligible for the study. In each hospital, microbiological speciation was conducted using the Vitek2 system (bioMérieux, Marcy l'Etoile, France) or the MicroScan system (Siemens Healthcare diagnostics, Tokyo, Japan). The ESBL screening test was performed according to the CLSI microdilution methodology (cefotaxime, ceftriaxone, ceftazidime, cefpodoxime, or aztreonam) [4].

2.2. Molecular analysis

Only the first isolate from each patient that was positive in the ESBL screen was sent to a reference laboratory (Kyoto University) and subjected to PCR amplification and sequencing of the *bla*_{SHV}, *bla*_{TEM}, *bla*_{OXA-1}, and *bla*_{CTX-M} genes and the 6 main groups of pAmpC-type genes [5]. All of the isolates with ESBL or pAmpC genes were further characterised based on their plasmid-mediated

quinolone resistance determinants (*qnrA*, *qnrB*, *qnrC*, *qnrS*, and *aac(6')-Ib-cr*) [5], their phylogenetic groups using triplex PCR (A, B1, B2, D, and non-typable) [5], integrases [6], and plasmid replicon typing [7] as has been previously described. Isolates that belonged to phylogenetic group B2 and were O25b PCR positive and O25b-*pabB* PCR positive were considered to belong to the ST131 clone [8]. Five selected ST131 isolates identified by these presumptive methods were confirmed by multilocus sequence typing according to the *E. coli* MLST Web site (<http://mlst.ucc.ie/mlst/dbs/Ecoli>). Random amplified polymorphic DNA (RAPD) fingerprinting using a DAF4 primer was also performed [5], and the profiles were analysed by GelCompar II, version 4.6 (Applied Maths, Sint-Martens-Latem, Belgium). Isolates with 100% similarity were designated as indistinguishable following the criteria by Tenover et al. [9]. Ciprofloxacin-non-susceptible isolates were sequenced to determine the quinolone resistance-determining regions (QRDRs) of *gyrA* and *parC* [10], and the correlated amino acids were compared with the corresponding regions of *E. coli* K-12 (GenBank accession no. NC000913).

2.3. Antimicrobial susceptibility testing

The antibiotic susceptibility was evaluated by microdilution using Dry Plate Eiken (Eiken, Tokyo, Japan) following CLSI specifications and interpreted according to the 2009 and 2011 CLSI criteria [4]. The ESBL confirmation test was performed using the double-disk synergy test following the CLSI guidelines [4].

2.4. Statistical analysis

Categorical variables were compared using the Fisher's exact test. A *P* value less than 0.05 was considered statistically significant.

3. Results and discussion

3.1. Prevalences of pAmpC or ESBL producers

During the study period, *E. coli* was isolated from a total of 1327 patients from 5 hospitals (Table 1). Of those isolates, 172 (13.0%) were positive in the ESBL screen. The PCR analysis identified 23

pAmpC producers and 129 ESBL producers, 4 of which were positive for both the pAmpC and the ESBL genes. The remaining 24 isolates contained neither pAmpC nor ESBL. The prevalence of pAmpC producers was 1.7%. CMY-2 was the most prevalent pAmpC type. Surveillance conducted between 2002 and 2008 in the Kinki region, which includes our study sites, showed that CMY-2 type was most prevalent [11]. However, the prevalence rate from our data (1.7%) seems to be substantially higher (0.1%) than that found previously. One possible explanation for this difference is that the prevalence has varied over time. We did not assess the yearly variation, but the prevalence of pAmpC producers has been increasing; for example, a Spanish study reported that the prevalence increased from 0.04% in 1997 to 1.1% in 2007. The prevalence of ESBL producers was 9.7%. In 2003, inpatient urine collected in 37 hospitals in Japan was studied, and the prevalence was 14% [12]. The SMART surveillance in 2009 reported a diverse prevalence within the Asia-Pacific region that ranged from 2.0% in Australia to 65.4% in China [13]. The prevalence of ESBL producers and pAmpC producers were higher in the 2 university hospitals than in the 3 municipal hospitals, which may be associated with the fact that university hospitals had less frequent community-acquired infections and had patients with more severe underlying diseases than municipal hospitals.

3.2. Antimicrobial susceptibility

Table 2 shows the characteristics of the pAmpC producers and the ESBL producers. The most frequent isolation source was urine. All of the isolates were susceptible to imipenem (minimum inhibitory concentration ≤ 1 $\mu\text{g/mL}$). Almost all of the ESBL producers were judged to be resistant to third-generation cephalosporins by the old CLSI breakpoints (prior to 2010) due to the positive results of the ESBL confirmation test. However, the revised breakpoints classified 66% of ESBL producers as susceptible to ceftazidime. This finding can be explained by the fact that 87% (42/48) of CTX-M-14-producers and 13% (4/31) of CTX-M-15-producers were susceptible to ceftazidime. This phenomenon is worth noting when implementing the revised breakpoints where CTX-M-14 is prevalent.

Less than one half of the pAmpC producers were determined to be resistant to

third-generation cephalosporins by old breakpoints, as all the isolates were negative in the ESBL confirmation test. The revised breakpoints correctly classified more than 90% of the pAmpC producers as resistant to third-generation cephalosporins. In Japan, the old breakpoints are still used, and the phenotype tests for the detection of pAmpC producers are rarely conducted. Furthermore, pAmpC producers are likely resistant to cefmetazole and piperacillin-tazobactam because of the activity of the pAmpC enzyme [3]. However, fewer than half were judged to be resistant. When ESBL screening-positive and ESBL confirmation-negative isolates are detected, the use of third-generation cephalosporins, cephamycins, or β -lactam/ β -lactam inhibitors requires caution irrespective of the susceptibilities of the isolates because the clinical efficacies of these drugs have not yet been established.

Twenty-four isolates without pAmpC or ESBL genes had reduced susceptibility rates to β -lactam/ β -lactam inhibitors (29% for ampicillin/sulbactam and 46% for piperacillin/tazobactam), and elevated chromosomal AmpC was a suggested mechanism of resistance.

3.3 Phylogenetic group, CTX-M type, and the ST131 clone isolates

Virulent phylogenetic groups B2 and D were prevalent in both pAmpC and ESBL producers. The CTX-M type, which is associated with the international emergence of the O25b-ST131-B2 clone, is now spreading worldwide [1]. CTX-M-15 is most closely associated with the ST131 clone, and thus is the most widely distributed CTX-M subtype. In our study, CTX-M-14 was the most prevalent ESBL, and CTX-M-15 was the second prevalent. Among 125 ESBL producers, 51 isolates of the ST131 clone (41%) were found. CTX-M-27 (41%) and CTX-M-15 (28%) were the most prevalent ESBLs in the ST131 clone isolates; however, CTX-M-27 was rarely found in non-ST131 clone isolates (2%). CTX-M-14 was the most frequent ESBL in non-ST131 isolates (41%). In the previous Japanese nationwide surveillance study, a significant portion of ESBL producers belonged to the ST131 and ST38 clones (approximately 20% each [14]. Most of the ST131 clone isolates contained CTX-M-14, but none of them contained CTX-M-15 or CTX-M-27 [14]. The prevalence of the ST131 clone has doubled, and the distribution of CTX-M types was quite different from that found in a

previous study. RAPD analysis showed that 135 of the 148 pAmpC or ESBL producers had distinguishable patterns. All of the 13 other isolates belonged to the ST131 clone and were composed of 1 cluster of 3 isolates and 5 clusters of 2 isolates. These results suggest that the ST131 clone is a dominant and unique clone among ESBL producers in our region.

The ST131 clone frequently contained genes for TEM-1, OXA-1, *aac(6')-Ib-cr*, and ciprofloxacin resistance [2]. In our study, the ST131 clone isolates had a higher ciprofloxacin non-susceptible rate (85%) than non-ST131 clone isolates (46%). Table 3 shows all of the ciprofloxacin non-susceptible isolates that had at least 3 mutations in QRDRs. All of the 46 ciprofloxacin non-susceptible ST131 clone isolates had double mutations both in GyrA (S83L and D87N) and ParC (S80I and E84V). This genotype was rarely found in the previous study in Asia [10]. On the contrary, 30 of 43 (70%) non-ST131 clone isolates had double mutations in GyrA (S83L and D87N) and a single mutation in ParC (S80I). This genotype was found worldwide, including in Asia [10]. A significantly smaller number of the ST131 clone isolates had TEM-1, which differed from previous studies [2]. The ST131 clone isolates frequently contained OXA-1 and *aac(6')-Ib-cr*, but the difference was not statistically significant. The ST131 clone isolates more frequently contained plasmid replicons for both IncFIA and IncFIB. Associations between CTX-M-15 producers and both IncFIA and IncFIB have been reported [7].

The ST131 clone accounted for only 2 of 19 pAmpC producing-isolates. These two isolates were susceptible to ciprofloxacin. The low prevalence of pAmpC-producing ST131 is consistent with the results of studies from Europe, which found a prevalence of less than 10% [15]. IncI1 was more frequently found in pAmpC producers than in ESBL producers. A Norwegian study reported a high prevalence of IncI1 among CMY-2 producers [15].

4. Conclusion

We found that 1.7% of *E. coli* isolates from clinical specimens were pAmpC producers. Among the ESBL producers, 41% were isolates of the ST131 clone, and these isolates were characterised by ciprofloxacin non-susceptibility with quadruple mutations in QRDRs, the presence of

175 CTX-M-27, the absence of TEM-1, and the plasmid replicons for IncFIA and IncFIB.

176

177 **Acknowledgements**

178 Funding: This work was supported by the Ministry of Health, Labour and Welfare of Japan

179 (H21-Shinkou-Ippan-008).

180 Competing interests: None declared.

181 Ethical approval: Not required.

References

1. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. *Clin Microbiol Infect.* 2008;14 Suppl 1:33-41.
2. Rogers BA, Sidjabat HE, Paterson DL. *Escherichia coli* O25b-ST131: a pandemic, multiresistant, community-associated strain. *J Antimicrob Chemother.* 2011;66:1-14.
3. Jacoby GA. AmpC beta-lactamases. *Clin Microbiol Rev.* 2009;22:161-82.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. CLSI document M100-S21. Wayne, PA, USA: CLSI; 2011.
5. Matsumura Y, Nagao M, Iguchi M, Yagi T, Komori T, Fujita N, et al. Molecular and clinical characterisation of plasmid-mediated AmpC β -lactamase-producing *Escherichia coli* bacteraemia: a comparison with extended-spectrum β -lactamase-producing and non-resistant *E. coli* bacteraemia. *Clin Microbiol Infect.* (in press)
6. Ploy MC, Denis F, Courvalin P, Lambert T. Molecular characterization of integrons in *Acinetobacter baumannii*: description of a hybrid class 2 integron. *Antimicrob Agents Chemother.* 2000;44:2684-8.
7. Mshana SE, Imirzalioglu C, Hossain H, Hain T, Domann E, Chakraborty T. Conjugative IncFI plasmids carrying CTX-M-15 among *Escherichia coli* ESBL producing isolates at a University hospital in Germany. *BMC Infect Dis.* 2009;9:97.
8. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al. Rapid detection of the O25b-ST131 clone of *Escherichia coli* encompassing the CTX-M-15-producing strains. *J Antimicrob Chemother.* 2009;64:274-7.
9. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol.* 1995;33:2233-9.
10. Uchida Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F, et al. Geographic distribution of fluoroquinolone-resistant *Escherichia coli* strains in Asia. *Int J*

- 209 Antimicrob Agents. 2010;35:387-91.
- 210 11. Yamasaki K, Komatsu M, Abe N, Fukuda S, Miyamoto Y, Higuchi T, et al.
- 211 Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the
- 212 Kinki region of Japan. J Clin Microbiol. 2010;48:3267-73.
- 213 12. Muratani T, Matsumoto T. Urinary tract infection caused by fluoroquinolone- and
- 214 cephem-resistant Enterobacteriaceae. Int J Antimicrob Agents. 2006;28 Suppl 1:S10-3.
- 215 13. Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, et al.
- 216 Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli
- 217 isolated from patients with intra-abdominal infections in the Asia-Pacific region according
- 218 to currently established susceptibility interpretive criteria. J Infect. 2011;62:280-91.
- 219 14. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the
- 220 prevalence of extended-spectrum-beta-lactamase-producing *Escherichia coli* in Japan by
- 221 clonal spread. J Antimicrob Chemother. 2009;63:72-9.
- 222 15. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of
- 223 CMY-2-producing multidrug-resistant *Escherichia coli* of ST-complexes 38 and 448, and
- 224 ST131 in Norway. Clin Microbiol Infect. 2010;16:171-8.
- 225
- 226

228 **Table 1. Prevalences of ESBL-producing and pAmpC-producing *E. coli* in each hospital.**

Hospital	Type of hospital	All isolates	ESBL screening		ESBL confirmation		ESBL ^a		pAmpC ^a		Both pAmpC and ESBL	
			test positive		test positive							
A	Municipal	350	35	(10.0%)	20	(5.7%)	20	(5.7%)	4	(1.1%)	1	(0.3%)
B	University	253	42	(16.6%)	33	(13.0%)	32	(12.6%)	7	(2.8%)	2	(0.8%)
C	Municipal	173	18	(10.4%)	17	(9.8%)	17	(9.8%)	1	(0.6%)	0	(0.0%)
D	Municipal	272	28	(10.3%)	23	(8.5%)	23	(8.5%)	5	(1.8%)	1	(0.4%)
E	University	279	49	(17.6%)	38	(13.6%)	37	(13.3%)	6	(2.2%)	0	(0.0%)
A, C, and D	Municipal	795	81	(10.2%)	60	(7.5%)	60	(7.5%)	10	(1.3%)	2	(0.3%)
B and E	University	532	91	(17.1%)	71	(13.3%)	69	(13.0%)	13	(2.4%)	2	(0.4%)
Total		1327	172	(13.0%)	131	(9.9%)	129	(9.7%)	23	(1.7%)	4	(0.3%)

229 All of the first isolates from each patient that were positive in the ESBL screening test were collected. The prevalences of ESBL producers and
 230 pAmpC producers were higher in the 2 university hospitals than in the 3 municipal hospitals ($P=0.001$ and $P=0.13$, respectively).

231 ^a The numbers included co-producers of pAmpC and ESBL.

232

233

234 **Table 2. Sources, in-vitro susceptibilities, and molecular characteristics of pAmpC-producing and ESBL-producing *E. coli*.**

Characteristic	pAmpC				Non-ST 131		
	pAmpC only (n=19)	ESBL only (n=125)	and ESBL (n=4)	<i>P</i> value ^a	ST131 clone (n=54)	clone (n=94)	<i>P</i> value
Source of isolates							
Urine	11 (58%)	83 (66%)	2 (50%)	0.61	40 (74%)	56 (60%)	0.11
Pus	4 (21%)	14 (11%)	0 (0%)	0.26	7 (13%)	11 (12%)	0.80
Blood	1 (5%)	9 (7%)	1 (25%)	1	1 (2%)	10 (11%)	0.06
Sputum	0 (0%)	5 (4%)	0 (0%)	1	5 (9%)	0 (0%)	0.006
Bile	0 (0%)	4 (3%)	1 (25%)	1	0 (0%)	5 (5%)	0.16
Others	3 (16%)	10 (8%)	0 (0%)	0.38	1 (2%)	12 (13%)	0.03
In-vitro susceptibility							
Cefepime	19 (100%)	86 (69%)	3 (75%)	0.002	39 (72%)	69 (73%)	1
Cefepime (old BP)	19 (100%)	0 (0%)	1 (25%)	<0.001	2 (4%)	18 (19%)	0.01
Cefotaxime	0 (0%)	2 (2%)	0 (0%)	1	1 (2%)	1 (1%)	1
Cefotaxime (old BP)	15 (79%)	0 (0%)	1 (25%)	<0.001	2 (4%)	14 (15%)	0.05

Ceftazidime	1 (5%)	82 (66%)	0 (0%)	<0.001	30 (56%)	53 (56%)	1
Ceftazidime (old BP)	9 (47%)	0 (0%)	1 (25%)	<0.001	1 (2%)	9 (10%)	0.09
Aztreonam	12 (63%)	50 (40%)	1 (25%)	0.08	21 (39%)	42 (45%)	0.61
Aztreonam (old BP)	15 (79%)	0 (0%)	1 (25%)	<0.001	2 (4%)	14 (15%)	0.05
Cefmetazole	10 (53%)	122 (98%)	2 (50%)	<0.001	52 (96%)	82 (87%)	0.08
Ampicillin-sulbactam	1 (5%)	45 (36%)	0 (0%)	0.007	25 (46%)	21 (22%)	0.003
Piperacillin-tazobactam	11 (58%)	96 (77%)	1 (25%)	0.09	47 (87%)	61 (65%)	0.004
Imipenem	19 (100%)	125 (100%)	4 (100%)	1	54 (100%)	94 (100%)	1
Amikacin	19 (100%)	125 (100%)	4 (100%)	1	54 (100%)	94 (100%)	1
Gentamicin	18 (95%)	103 (82%)	4 (100%)	0.31	48 (89%)	77 (82%)	0.35
Ciprofloxacin	14 (74%)	43 (34%)	2 (50%)	0.002	8 (15%)	51 (54%)	<0.001
Trimethoprim-sulfamethoxazole	10 (53%)	67 (54%)	2 (50%)	1	31 (57%)	48 (51%)	0.50
Minocycline	11 (58%)	93 (74%)	2 (50%)	0.17	46 (85%)	60 (64%)	0.008
Colistin	19 (100%)	125 (100%)	4 (100%)	1	54 (100%)	94 (100%)	1
ESBL confirmation test	0 (0%)	125 (100%)	3 (75%)	<0.001	52 (96%)	76 (81%)	0.01

Resistance gene

CMY-2	18 (95%)	0 (0%)	4 (100%)	<0.001	2 (4%)	20 (21%)	0.003
DHA-1	1 (5%)	0 (0%)	0 (0%)	0.14	1 (2%)	0 (0%)	0.37
CTX-M-14 ^b	0 (0%)	50 (40%)	0 (0%)	<0.001	11 (20%)	39 (41%)	0.01
CTX-M-15 ^b	0 (0%)	33 (26%)	1 (25%)	0.007	15 (28%)	18 (19%)	0.31
CTX-M-27	0 (0%)	24 (19%)	0 (0%)	0.04	22 (41%)	2 (2%)	<0.001
CTX-M-2	0 (0%)	10 (8%)	1 (25%)	0.36	1 (2%)	10 (11%)	0.06
CTX-M-24	0 (0%)	4 (3%)	0 (0%)	1	2 (4%)	2 (2%)	0.62
CTX-M-1	0 (0%)	2 (2%)	2 (50%)	1	0 (0%)	2 (2%)	1
CTX-M-3	0 (0%)	0 (0%)	1 (25%)	1	0 (0%)	1 (1%)	0.37
CTX-M-9	0 (0%)	2 (2%)	0 (0%)	1	0 (0%)	1 (1%)	0.37
CTX-M-44	0 (0%)	1 (1%)	1 (25%)	1	0 (0%)	1 (1%)	0.37
CTX-M-65	0 (0%)	1 (1%)	0 (0%)	1	0 (0%)	1 (1%)	0.37
SHV type ESBL	0 (0%)	3 (2%)	0 (0%)	1	1 (2%)	2 (2%)	1
TEM-1	8 (42%)	45 (36%)	2 (50%)	0.62	12 (22%)	43 (46%)	0.005
OXA-1	0 (0%)	4 (3%)	0 (0%)	1	3 (6%)	1 (1%)	0.14

<i>qnr^c</i>	1 (5%)	3 (2%)	0 (0%)	0.44	1 (2%)	3 (3%)	0.46
<i>aac(6')-Ib-cr</i>	0 (0%)	5 (4%)	0 (0%)	1	4 (7%)	1 (1%)	0.06
Phylogenetic group							
A	2 (11%)	4 (3%)	0 (0%)	0.18	0 (0%)	6 (6%)	0.08
B1	2 (11%)	9 (7%)	1 (25%)	0.64	0 (0%)	12 (13%)	0.004
B2	6 (32%)	66 (53%)	2 (50%)	0.14	54 (100%)	20 (21%)	<0.001
D	7 (37%)	43 (34%)	1 (25%)	0.80	0 (0%)	51 (54%)	<0.001
Non-typable	2 (11%)	3 (2%)	0 (0%)	0.13	0 (0%)	5 (5%)	0.16
ST131 clone	2 (11%)	51 (41%)	1 (25%)	0.01	54 (100%)	0 (0%)	<0.001
Class 1 integrase ^d	10 (53%)	61 (49%)	2 (50%)	0.81	25 (46%)	48 (51%)	0.61
Plasmid replicon type ^e							
IncFIA	0 (0%)	20 (16%)	1 (25%)	0.07	13 (24%)	8 (9%)	0.01
IncFIA and IncFIB	4 (21%)	51 (41%)	1 (25%)	0.13	33 (61%)	23 (24%)	<0.001
IncFIB	6 (32%)	29 (23%)	1 (25%)	0.41	5 (9%)	31 (33%)	0.001
IncII	10 (53%)	26 (21%)	4 (100%)	0.008	7 (13%)	33 (35%)	0.004

235 The data are presented as the number (%).

236 All in vitro susceptibilities were evaluated using the revised CLSI breakpoints for 2011 except those for the antibiotics labeled “old BP”; for these

237 antibiotics, the susceptibility was evaluated using the old CLSI breakpoints for 2009 with modification of the category if the ESBL confirmation test
238 was positive. For colistin, all of the isolates in this study had minimum inhibitory concentrations of ≤ 2 $\mu\text{g/mL}$.
239 ^a *P* value for the comparison between pAmpC-only and ESBL-only isolates.
240 ^b Two ESBL-producing isolates (one ST131 clone and one non-ST131 clone) were positive for CTX-M-14 and CTX-M-15.
241 ^c *qnrB* was found in the pAmpC and ST131 group. *qnrS* was found in the ESBL and non-ST131 group.
242 ^d Class 2 and class 3 integrase genes were not found.
243 ^e The 4 most prevalent replicon types are listed. The A/C, P, B/O, K/B, N, and Y types were found, but the prevalences were less than 10%.
244

245 **Table 3. Molecular mechanism of quinolone resistance among ciprofloxacin non-susceptible ESBL-producing *E. coli*.**

Clone type	Number of isolates	Amino acid mutations in QRDR				Number of isolates with <i>aac(6')-Ib-cr</i>
		GyrA		ParC		
		83	87	80	84	
ST131 clone	46	L	N	I	V	4
Non-ST131 clone	30	L	N	I	E	0
	5	L	N	I	G	1
	2	L	N	I	V	0
	2	L	Y	I	E	0
	1	L	N	I	A	0
	1	L	N	I	K	0
	1	L	N	I	S	0
	1	L	N	R	E	0
Wild type (<i>E.coli</i> K-12)	-	S	D	S	E	-

246 All of these isolates lacked *qnr*.